Spetzler David Baxley sold $14.8M of CAI

Spetzler David Baxley (President) sold 597,212 shares of Caris Life Sciences, Inc. (CAI) at an average of $24.84 ($24.76–$25.32, $14.83M total) across 3 trades over 2026-09-03 to 2026-09-04.

Original reporting
SEC EDGAR · Spetzler David Baxley
Published Sep 4, 2026, 8:59 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 10:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CAI
Bearish
medium confidence
Mentioned
$CAI
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CAIBearishLow
01

Why it matters

The sale represents a direct reduction in insider ownership, which can be interpreted as a negative signal by the market.

02

Market read

Insider sell of $14.8M is material for CAI and may influence short‑term price action.

03

What to watch

Potential tax planning or liquidity needs unrelated to company outlook.

Relevance 7/10Novelty 8/10Timing: filing today

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$CAIBearishMedium confidence
Context

President Spetzler David Baxley sold 597,212 shares of Caris Life Sciences for $14.8M, reducing his stake to 1.18M shares.

Expected impact

Modest downside pressure in the near term.

Evidence & confidence

A $14.8M sale by a top executive is material; markets often react negatively to insider disposals of this size.

Market effects

May raise concerns about biotech sector insider sentiment.

Limited to U.S. biotech investors.

Minimal global impact.

Counterpoint

Insider may be diversifying; sale does not necessarily reflect company fundamentals.

Key entities

  • Caris Life Sciences, Inc.

    Biotech firm developing AI-driven cancer diagnostics.

  • Spetzler David Baxley

    President of Caris Life Sciences.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CAIMed

Caris Life Sciences Inc (CAI) Q3 2026 Earnings Call Highlights: Record Revenue, Sixth

Caris Life Sciences (CAI) reported Q3 2026 revenue growth, but faced negative free cash flow of $39.7M due to capital expenditures. Operating expenses rose $48.1M year-over-year, and full-year GAAP opex guidance was raised to ~$620M. New product launches without reimbursement may pressure margins. Q4 pharma R&D services revenue is expected to decline sequentially. The company is expanding its commercial team and expects positive free cash flow in Q4.

$CAIHigh

Caris Life (CAI) Q3 2026 Earnings Call Transcript

Caris Life (CAI) reported Q3 2026 earnings, highlighting 21% year-over-year clinical case growth and 27% revenue increase to $275M. The company launched new products, including Caris Assure for monitoring and plans to launch Caris Confirm for MRD in December. Caris Detect, their early-stage cancer detection test, is gaining market traction. The company maintained profitability with adjusted EBITDA of $44.4M and net income of $15.3M.

$CAIMed

TD Cowen raises Caris Life Sciences stock price target on pipeline

TD Cowen raised its price target for Caris Life Sciences (CAI) to $38 from $36, maintaining a Buy rating. The company reported Q3 sales beating expectations by 9%, with revenue up 85% year-over-year and a 70% gross margin. Despite this, shares fell 15% post-market due to an earnings miss. The stock has gained 65% since pre-Q2 levels, but InvestingPro suggests it may be overvalued.